Gonadotropin-releasing hormone-Agonist triggering and a freeze-All approach: The final step in eliminating ovarian hyperstimulation syndrome?

Obstetrical and Gynecological Survey

Volumn 72, Issue 5, 2017, Pages 296-308

  Davenpor, Marcus J ^a   Vollenhoven, Beverley ^a,b,c   Talmor, Alon J ^a,c  

^a MONASH UNIVERSITY   (Australia)

^b SOUTHERN HEALTH   (Australia)

^c MONASH IVF   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; FOLLITROPIN; GONADORELIN AGONIST; LUTEINIZING HORMONE; PROGESTERONE; GONADORELIN;

BODY MASS; CRYOPRESERVATION; DONOR SELECTION; DOWN REGULATION; ELECTIVE EMBRYO CRYOPRESERVATION; FINE NEEDLE ASPIRATION BIOPSY; HUMAN; INTRACYTOPLASMIC SPERM INJECTION; LUTEAL PHASE; OOCYTE RETRIEVAL; OVARY HYPERSTIMULATION; PATHOGENESIS; PREGNANCY; PREGNANCY OUTCOME; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SPONTANEOUS ABORTION; SYSTEMATIC REVIEW; TREATMENT OUTCOME; AGONISTS; EMBRYO TRANSFER; FEMALE; IN VITRO FERTILIZATION; OVULATION INDUCTION; PREGNANCY RATE; PROCEDURES;

CRYOPRESERVATION; EMBRYO TRANSFER; FEMALE; FERTILIZATION IN VITRO; GONADOTROPIN-RELEASING HORMONE; HUMANS; OVARIAN HYPERSTIMULATION SYNDROME; OVULATION INDUCTION; PREGNANCY; PREGNANCY RATE;

EID: 85020673599     PISSN: 00297828     EISSN: 15339866     Source Type: Journal    
DOI: 10.1097/OGX.0000000000000432     Document Type: Review

References (100)

1. Farquhar C, Rishworth JR, Brown J, et al. Assisted reproductive technology: An overview of Cochrane reviews. Cochrane Database Syst Rev. 2014;12:CD010537.
2. Bauquis C. ESHRE Press Release: 5 million babies. European Society of Human Reproduction and Embryology; 2012.
3. Braat DD, Schutte JM, Bernardus RE, et al. Maternal death related to IVF in the Netherlands 1984-2008. Hum Reprod. 2010;25:1782-1786.
4. Gonen Y, Balakier H, Powell W, et al. Use of gonadotropinreleasing hormone agonist to trigger follicular maturation for in vitro fertilization. J Clin Endocrinol Metab. 1990;71:918-922.
5. Acevedo B, Gomez-Palomares JL, Ricciarelli E, et al. Triggering ovulation with gonadotropin-releasing hormone agonists does not compromise embryo implantation rates. Fertil Steril. 2006; 86:1682-1687.
6. Babayof R, Margalioth EJ, Huleihel M, et al. Serum inhibin A, VEGF and TNFalpha levels after triggering oocyte maturation with GnRH agonist compared with hCG in women with polycystic ovaries undergoing IVF treatment: A prospective randomized trial. Hum Reprod. 2006;21:1260-1265.
7. Humaidan P, Ejdrup Bredkjaer H, Westergaard LG, et al. 1, 500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: A prospective, randomized, controlled study. Fertil Steril. 2010;93:847-854.
8. Griesinger G, von Otte S, Schroer A, et al. Elective cryopreservation of all pronuclear oocytes after GnRH agonist triggering of final oocyte maturation in patients at risk of developing OHSS: A prospective, observational proof-of-concept study. Hum Reprod. 2007;22:1348-1352.
9. Maheshwari A, Pandey S, Shetty A, et al. Obstetric and perinatal outcomes in singleton pregnancies resulting fromthe transfer of frozen thawed versus fresh embryos generated through in vitro fertilization treatment: A systematic review and meta-Analysis. Fertil Steril. 2012;98:368-377.e1-e9.
10. Devroey P, Polyzos NP, Blockeel C. An OHSS-Free Clinic by segmentation of IVF treatment.Hum Reprod. 2011;26:2593-2597.
11. Fatemi HM, Popovic-Todorovic B, Humaidan P, et al. Severe ovarian hyperstimulation syndrome after gonadotropin-releasing hormone (GnRH) agonist trigger and "freeze-All" approach in GnRH antagonist protocol. Fertil Steril. 2014;101:1008-1011.
12. Ling LP, Phoon JW, Lau MS, et al. GnRH agonist trigger and ovarian hyperstimulation syndrome: Relook at 'freeze-All strategy'. Reprod Biomed Online. 2014;29:392-394.
13. Gurbuz AS, Gode F, Ozcimen N, et al. Gonadotrophin-releasing hormone agonist trigger and freeze-All strategy does not prevent severe ovarian hyperstimulation syndrome: A report of three cases. Reprod Biomed Online. 2014;29:541-544.
14. Kessler MJ, Reddy MS, Shah RH, et al. Structures of N-glycosidic carbohydrate units of human chorionic gonadotropin. J Biol Chem. 1979;254:7901-7908.
15. Rabau E, David A, Serr DM, et al. Human menopausal gonadotropins for anovulation and sterility. Results of 7 years of treatment. Am J Obstet Gynecol. 1967;98:92-98.
16. Golan A, Ron-El R, Herman A, et al. Ovarian hyperstimulation syndrome: An update review. Obstet Gynecol Surv. 1989;44:430-440.
17. Delvigne A, Rozenberg S. Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): A review. Hum Reprod Update. 2002;8:559-577.
18. Gómez R, Soares SR, Busso C, et al. Physiology and pathology of ovarian hyperstimulation syndrome. Semin Reprod Med. 2010; 28:448-457.
19. Raziel A, Schachter M, Friedler S, et al. Outcome of IVF pregnancies following severe OHSS. Reprod Biomed Online. 2009;19:61-65.
20. Goldsman MP, Pedram A, Dominguez CE, et al. Increased capillary permeability induced by human follicular fluid: A hypothesis for an ovarian origin of the hyperstimulation syndrome. Fertil Steril. 1995;63:268-272.
21. Smitz J, Camus M, Devroey P, et al. Incidence of severe ovarian hyperstimulation syndrome afterGnRHagonist/HMGsuperovulation for in-vitro fertilization. Hum Reprod. 1990;5:933-937.
22. Navot D, Bergh PA, Laufer N. Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertil Steril. 1992;58:249-261.
23. Lee TH, Liu CH, Huang CC, et al. Serum anti-müllerian hormone and estradiol levels as predictors of ovarian hyperstimulation syndrome in assisted reproduction technology cycles. Hum Reprod. 2008;23:160-167.
24. Asch RH, Li HP, Balmaceda JP, et al. Severe ovarian hyperstimulation syndrome in assisted reproductive technology: definition of high risk groups. Hum Reprod. 1991;6:1395-1399.
25. Papanikolaou EG, Pozzobon C, Kolibianakis EM, et al. Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles. Fertil Steril. 2006;85:112-120.
26. Mathur RS, Akande AV, Keay SD, et al. Distinction between early and late ovarian hyperstimulation syndrome. Fertil Steril. 2000;73:901-907.
27. Papanikolaou EG, Tournaye H, Verpoest W, et al. Early and late ovarian hyperstimulation syndrome: Early pregnancy outcome and profile. Hum Reprod. 2005;20:636-641.
28. Al-Inany H, Aboulghar M. Gonadotrophin-releasing hormone antagonists for assisted conception. Cochrane Database Syst Rev. 2001;4:CD001750.
29. Al-Inany HG, Abou-Setta AM, Aboulghar M. Gonadotrophinreleasing hormone antagonists for assisted conception. Cochrane Database Syst Rev. 2006;3:CD001750.
30. Al-Inany HG, Youssef MA, Aboulghar M, et al. Gonadotrophinreleasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev. 2011;5:CD001750.
31. Kolibianakis EM, Collins J, Tarlatzis BC, et al. Among patients treated for IVF with gonadotrophins and GnRH analogues, is the probability of live birth dependent on the type of analogue used? A systematic review and meta-Analysis. Hum Reprod Update. 2006;12:651-671.
32. Klingmüller D, Schepke M, Enzweiler C, et al. Hormonal responses to the new potent GnRH antagonist cetrorelix. Acta Endocrinol (Copenh). 1993;128:15-18.
33. Varney NR, Syrop C, Kubu CS, et al. Neuropsychologic dysfunction in women following leuprolide acetate induction of hypoestrogenism. J Assist Reprod Genet. 1993;10:53-57.
34. Boerrigter PJ, de Bie JJ, Mannaerts BM, et al. Obstetrical and neonatal outcome after controlled ovarian stimulation for IVF using the GnRH antagonist ganirelix. Hum Reprod. 2002; 17:2027-2034.
35. Taylor JE, Miller BT, Gray KD, et al. The mechanism responsible for the supraphysiologic gonadotropin surge in females treated with gonadotropin-releasing hormone (GnRH) agonist and primed with GnRH antagonist. Fertil Steril. 2010;93: 1668-1675.
36. Fauser BC, de Jong D, Olivennes F, et al. Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization. J Clin Endocrinol Metab. 2002;87:709-715.
37. Melo M, Busso CE, Bellver J, et al. GnRH agonist versus recombinant hCG in an oocyte donation programme: A randomized, prospective, controlled, assessor-blind study. Reprod Biomed Online. 2009;19:486-492.
38. Galindo A, Bodri D, Guillén JJ, et al. Triggering with hCG or GnRH agonist in GnRH antagonist treated oocyte donation cycles: A randomised clinical trial. Gynecol Endocrinol. 2009; 25:60-66.
39. Sismanoglu A, Tekin HI, Erden HF, et al. Ovulation triggering with GnRH agonist vs. hCG in the same egg donor population undergoing donor oocyte cycles with GnRH antagonist: A prospective randomized cross-over trial. J Assist Reprod Genet. 2009;26:251-256.
40. Sugino N, Kashida S, Takiguchi S, et al. Expression of vascular endothelial growth factor and its receptors in the human corpus luteumduring themenstrual cycle and in early pregnancy. J Clin Endocrinol Metab. 2000;85:3919-3924.
41. Beckers NG, Macklon NS, Eijkemans MJ, et al. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant folliclestimulating hormone and GnRH antagonist cotreatment. J Clin Endocrinol Metab. 2003;88:4186-4192.
42. Fauser BC, Devroey P. Reproductive biology and IVF: ovarian stimulation and luteal phase consequences. Trends Endocrinol Metab. 2003;14:236-242.
43. Humaidan P, Bredkjaer HE, Bungum L, et al. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: A prospective randomized study. Hum Reprod. 2005;20:1213-1220.
44. Kolibianakis EM, Schultze-Mosgau A, Schroer A, et al. A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of hCG in patients undergoing IVF with GnRH antagonists. Hum Reprod. 2005;20:2887-2892.
45. Griesinger G, Diedrich K, Devroey P, et al. GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: A systematic review and meta-Analysis. Hum Reprod Update. 2006;12:159-168.
46. Griesinger G, Kolibianakis EM, Papanikolaou EG, et al. Triggering of final oocytematurationwith gonadotropin-releasing hormone agonist or human chorionic gonadotropin. Live birth after frozenthawed embryo replacement cycles. Fertil Steril. 2007;88:616-621.
47. Tavaniotou A, Smitz J, Bourgain C, et al. Ovulation induction disrupts luteal phase function. Ann N Y Acad Sci. 2001;943:55-63.
48. Rao CV. Multiple novel roles of luteinizing hormone. Fertil Steril. 2001;76:1097-1100.
49. Pritts EA, Atwood AK. Luteal phase support in infertility treatment: A meta-Analysis of the randomized trials. Hum Reprod. 2002;17:2287-2299.
50. Engmann L, Siano L, Schmidt D, et al. GnRH agonist to induce oocyte maturation during IVF in patients at high risk of OHSS. Reprod Biomed Online. 2006;13:639-644.
51. Engmann L, DiLuigi A, Schmidt D, et al. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: A prospective randomized controlled study. Fertil Steril. 2008;89:84-91.
52. Engmann L, DiLuigi A, Schmidt D, et al. The effect of luteal phase vaginal estradiol supplementation on the success of in vitro fertilization treatment: A prospective randomized study. Fertil Steril. 2008;89:554-561.
53. Shapiro BS, Daneshmand ST, Garner FC, et al. Comparison of "triggers" using leuprolide acetate alone or in combination with low-dose human chorionic gonadotropin. Fertil Steril. 2011;95:2715-2717.
54. Iliodromiti S, Lan VT, Tuong HM, et al. Impact of GnRH agonist triggering and intensive luteal steroid support on live-birth rates and ovarian hyperstimulation syndrome: A retrospective cohort study. J Ovarian Res. 2013;6:93.
55. O'Neill KE, Senapati S, Dokras A. Use of gonadotropinreleasing hormone agonist trigger during in vitro fertilization is associated with similar endocrine profiles and oocytemeasures in women with and without polycystic ovary syndrome. Fertil Steril. 2015;103:264-269.
56. Farhi J, Weissman A, Steinfeld Z, et al. Estradiol supplementation during the luteal phase may improve the pregnancy rate in patients undergoing in vitro fertilization-embryo transfer cycles. Fertil Steril. 2000;73:761-766.
57. Fatemi HM, Kolibianakis EM, Camus M, et al. Addition of estradiol to progesterone for luteal supplementation in patients stimulated with GnRH antagonist/rFSH for IVF: A randomized controlled trial. Hum Reprod. 2006;21:2628-2632.
58. Humaidan P, Bungum L, Bungum M, et al. Rescue of corpus luteum function with peri-ovulatory hCG supplementation in IVF/ICSI GnRH antagonist cycles in which ovulation was triggered with a GnRH agonist: A pilot study. Reprod Biomed Online. 2006;13:173-178.
59. Humaidan P, Quartarolo J, Papanikolaou EG. Preventing ovarian hyperstimulation syndrome: guidance for the clinician. Fertil Steril. 2010;94:389-400.
60. Humaidan P, Polyzos NP, Alsbjerg B, et al. GnRHa trigger and individualized luteal phase hCGsupport according to ovarian response to stimulation: Two prospective randomized controlled multicentre studies in IVF patients. Hum Reprod. 2013;28:2511-2521.
61. Humaidan P. Luteal phase rescue in high-risk OHSS patients by GnRHa triggering in combination with low-dose hCG: A pilot study. Reprod Biomed Online. 2009;18:630-634.
62. Radesic B, Tremellen K. Oocyte maturation employing a GnRH agonist in combination with low-dose hCG luteal rescue minimizes the severity of ovarian hyperstimulation syndrome while maintaining excellent pregnancy rates. Hum Reprod. 2011;26:3437-3442.
63. Iliodromiti S, Blockeel C, Tremellen KP, et al. Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: A retrospective multicentre study. Hum Reprod. 2013;28:2529-2536.
64. Datta AK, Eapen A, Birch H, et al. Retrospective comparison of GnRH agonist trigger with hCG trigger in GnRH antagonist cycles in anticipated high-responders. Reprod Biomed Online. 2014;29:552-558.
65. Castillo JC, Dolz M, Bienvenido E, et al. Cycles triggered with GnRH agonist: Exploring low-dose hCG for luteal support. Reprod Biomed Online. 2010;20:175-181.
66. Haas J, Kedem A, Machtinger R, et al. hCG(1500 IU) administration on day 3 after oocytes retrieval, following GnRH-Agonist trigger for final follicular maturation, results in high sufficient mid luteal progesterone levels-A proof of concept. J Ovarian Res. 2014;7:35.
67. van der Linden M, Buckingham K, Farquhar C, et al. Luteal phase support for assisted reproduction cycles. CochraneDatabase Syst Rev. 2011;10:CD009154.
68. van der Linden M, Buckingham K, Farquhar C, et al. Luteal phase support for assisted reproduction cycles. CochraneDatabase Syst Rev. 2015;7:CD009154.
69. Pirard C, Donnez J, Loumaye E. GnRH agonist as luteal phase support in assisted reproduction technique cycles: Results of a pilot study. Hum Reprod. 2006;21:1894-1900.
70. Papanikolaou EG, Verpoest W, Fatemi H, et al. A novel method of luteal supplementation with recombinant luteinizing hormone when a gonadotropin-releasing hormone agonist is used instead of human chorionic gonadotropin for ovulation triggering: A randomized prospective proof of concept study. Fertil Steril. 2011;95:1174-1177.
71. Youssef MA, AlInany HG, Evers JL, et al. Intra-venous fluids for the prevention of severe ovarian hyperstimulation syndrome. Cochrane Database Syst Rev. 2011;2:CD001302.
72. Youssef MA, van der Veen F, Al-Inany HG, et al. Gonadotropinreleasing hormone agonist versus hCG for oocyte triggering in antagonist-Assisted reproductive technology. Cochrane Database Syst Rev. 2014;10:CD008046.
73. Budinetz TH, Mann JS, Griffin DW, et al. Maternal and neonatal outcomes after gonadotropin-releasing hormone agonist trigger for final oocyte maturation in patients undergoing in vitro fertilization. Fertil Steril. 2014;102:753-758.
74. Awonuga AO, Pittrof RJ, Zaidi J, et al. Elective cryopreservation of all embryos in women at risk of developing ovarian hyperstimulation syndrome may not prevent the condition but reduces the live birth rate. J Assist Reprod Genet. 1996;13: 401-406.
75. Ferraretti AP, Gianaroli L, Magli C, et al. Elective cryopreservation of all pronucleate embryos in women at risk of ovarian hyperstimulation syndrome: Efficiency and safety. Hum Reprod. 1999;14:1457-1460.
76. Griesinger G, Berndt H, Schultz L, et al. Cumulative live birth rates after GnRH-Agonist triggering of final oocyte maturation in patients at risk of OHSS: A prospective, clinical cohort study. Eur J Obstet Gynecol Reprod Biol. 2010;149:190-194.
77. Griesinger G, Schultz L, Bauer T, et al. Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropinreleasing hormone antagonist protocol in combination with a "freeze-All" strategy: A prospective multicentric study. Fertil Steril. 2011;95:2029-2033, 2033.e1.
78. Roque M, Lattes K, Serra S, et al. Fresh embryo transfer versus frozen embryo transfer in in vitro fertilization cycles: A systematic review and meta-Analysis. Fertil Steril. 2013;99:156-162.
79. Roy TK, Bradley CK, Bowman MC, et al. Single-embryo transfer of vitrified-warmed blastocysts yields equivalent live-birth rates and improved neonatal outcomes compared with fresh transfers. Fertil Steril. 2014;101:1294-1301.
80. Li Z, Wang YA, Ledger W, et al. Clinical outcomes following cryopreservation of blastocysts by vitrification or slow freezing: A population-based cohort study. Hum Reprod. 2014;29:2794-2801.
81. Papanikolaou EG, Kolibianakis EM, Tournaye H, et al. Live birth rates after transfer of equal number of blastocysts or cleavagestage embryos in IVF. A systematic review and meta-Analysis. Hum Reprod. 2008;23:91-99.
82. Evans J, Hannan NJ, Edgell TA, et al. Fresh versus frozen embryo transfer: backing clinical decisions with scientific and clinical evidence. Hum Reprod Update. 2014;20:808-821.
83. Shapiro BS, Daneshmand ST, Garner FC, et al. Evidence of impaired endometrial receptivity after ovarian stimulation for in vitro fertilization: A prospective randomized trial comparing fresh and frozen-Thawed embryo transfers in high responders. Fertil Steril. 2011;96:516-518.
84. Navot D, Bergh P. Preparation of the human endometrium for implantation. Ann N Y Acad Sci. 1991;622:212-219.
85. Thomas K, Thomson AJ, Sephton V, et al. The effect of gonadotrophic stimulation on integrin expression in the endometrium. Hum Reprod. 2002;17:63-68.
86. Bourgain C, Devroey P. The endometrium in stimulated cycles for IVF. Hum Reprod Update. 2003;9:515-522.
87. Fatemi HM, Garcia-Velasco J. Avoiding ovarian hyperstimulation syndrome with the use of gonadotropin-releasing hormone agonist trigger. Fertil Steril. 2015;103:870-873.
88. Macaldowie A, Wang YA, Chambers GM, et al. Assisted Reproductive Technology in Australia and New Zealand 2011.Sydney, Australia: National Perinatal Epidemiology and Statistics Unit, The University of New South Wales; 2013.
89. Roy TK, Brandi S, Tappe NM, et al. Embryo vitrification using a novel semi-Automated closed system yields in vitro outcomes equivalent to the manual Cryotop method. Hum Reprod. 2014; 29:2431-2438.
90. Loutradi KE, Kolibianakis EM, Venetis CA, et al. Cryopreservation of human embryos by vitrification or slow freezing: A systematic review and meta-Analysis. Fertil Steril. 2008;90:186-193.
91. Solé M, Santaló J, Boada M, et al. How does vitrification affect oocyte viability in oocyte donation cycles? A prospective study to compare outcomes achievedwith fresh versus vitrified sibling oocytes. Hum Reprod. 2013;28:2087-2092.
92. Schoolcraft WB, Keller JL, Schlenker T. Excellent embryo quality obtained from vitrified oocytes. Reprod Biomed Online. 2009;19:820-823.
93. Pandey S, Shetty A, Hamilton M, et al. Obstetric and perinatal outcomes in singleton pregnancies resulting from IVF/ICSI: A systematic review and meta-Analysis. Hum Reprod Update. 2012;18:485-503.
94. Cobo A, Serra V, Garrido N, et al. Obstetric and perinatal outcome of babies born from vitrified oocytes. Fertil Steril. 2014;102:1006-1015 e4.
95. Pelkonen S, Koivunen R, Gissler M, et al. Perinatal outcome of children born after frozen and fresh embryo transfer: The Finnish cohort study 1995-2006. Hum Reprod. 2010;25:914-923.
96. Wennerholm UB, Söderström-Anttila V, Bergh C, et al. Children born after cryopreservation of embryos or oocytes: A systematic review of outcome data. Hum Reprod. 2009;24:2158-2172.
97. Liu SY, Teng B, Fu J, et al. Obstetric and neonatal outcomes after transfer of vitrified early cleavage embryos. Hum Reprod. 2013;28:2093-2100.
98. Shapiro BS, Daneshmand ST, De Leon L, et al. Frozen-Thawed embryo transfer is associated with a significantly reduced incidence of ectopic pregnancy. Fertil Steril. 2012;98:1490-1494.
99. Kansal Kalra S, Ratcliffe SJ, Milman L, et al. Perinatal morbidity after in vitro fertilization is lower with frozen embryo transfer. Fertil Steril. 2011;95:548-553.
100. Imudia AN, Awonuga AO, Doyle JO, et al. Peak serum estradiol level during controlled ovarian hyperstimulation is associated with increased risk of small for gestational age and preeclampsia in singleton pregnancies after in vitro fertilization. Fertil Steril. 2012;97:1374-1379.